Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 64

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 64
---
. government entity, such as the Committee on Foreign Investment in the United States      
 (“CFIUS”). As a result, the pool of potential targets with which we could complete            
 the Business Combination may be limited. In addition, the time necessary for any governmental 
 or regulatory review or approval could prevent us from completing the Business Combination    
 and require us to liquidate.                                                                  |

| ● | The                                                                              
 combined company does not currently intend to pay dividends on its common stock. |

| ● | Future                                                                              
 sales of shares of the combined company’s common stock may depress its stock price. |

| ● | Exclusive                                                                                         
 forum provisions in the combined company’s Bylaws could limit our stockholders’                   
 ability to choose their preferred judicial forum for disputes with us or our directors, officers, 
 or employees.                                                                                     |

| ● | Longevity                                                                                  
 currently has no operating history and is acquiring certain technologies and businesses in 
 connection with the Business Combination, and therefore Longevity currently has no sources 
 of revenue. It may never become profitable.                                                |

| ● | The                                                                                           
 clinical study process required to obtain regulatory approvals or certifications carries      
 substantial risks and is lengthy and expensive with uncertain outcomes. If Longevity’s        
 clinical studies are unsuccessful or significantly delayed, or if Longevity does not complete 
 its clinical studies, Longevity’s business may be harmed.                                     |

| ● | Even                                                                                     
 if Longevity obtains all necessary FDA approvals, its product candidates may not achieve 
 or maintain market acceptance.                                                           |

| ● | Longevity’s                                                                                       
 operating results may fluctuate significantly, which makes its future operating results difficult 
 to predict and could cause its operating results to fall below expectations or any guidance       
 it may provide.                                                                                   |

| 18 |

| ● | Longevity                                                                                      
 may need to raise additional capital to fund its existing operations and achieve its goals.    
 If Longevity is unable to raise additional capital when needed on acceptable terms or generate 
 cash flows necessary to maintain or expand its operations, it may not be able to compete       
 successfully, which would harm its business, results of operations, and financial condition.   |

| ● | Longevity                                                                                  
 is dependent on third party manufacturers, as well as third parties, for its supply chain, 
 which could expose it to a number of risks that may delay development, regulatory approval 
 and commercialization or result in higher product costs.                                   |

| ● | Longevity                                                                                          
 relies on third parties to manufacture its product candidates, and it expects to continue          
 to